Share Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026

GlobeNewsWire · RVMD · November 19, 2026

Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026

Stocks To Buy Now app

Get the app for more

Explore stock news, insights and company research.

Get the app →
Source: GlobeNewsWire ↗